Potential five-year life years associated with stage IV reductions in NHS Galleri Trial

The NHS-Galleri trial did not reach its prespecified primary endpoint of reducing combined stage III and IV cases, but it reported fewer stage IV cancers after annual multi-cancer early detection screening. This analysis estimated the potential five-year life-years linked to the cancer-specific stage IV differences observed during the two incident screening rounds.

The researchers used intervention and control stage IV counts for ten prespecified cancers from NHS-Galleri. For each cancer, they multiplied the randomized-arm count difference by the difference in five-year restricted mean survival time between stage III and IV, estimated from England stage-specific five-year net survival with a constant-hazard fit. Adverse cancer-specific differences were retained in the model, and results were annualized across the two incident rounds and scaled per million people screened; sampling intervals used an independent Poisson approximation for arm-specific counts.

Across ten evaluable cancers, the intervention and control arms had 180 and 239 stage IV diagnoses during the incident rounds. The conditional projection was 66.3 potential life-years over five years in the trial intervention cohort, equivalent to 466 per million people screened annually (95% sampling interval 190–743).

For a population of 10 million, the corresponding projection was 4,664 annually (1,896–7,432). Colorectal, lung, and esophageal cancers accounted for 79% of the net projection, while pancreatic, ovarian, and lymphoid cancers contributed negatively because their observed stage IV counts favored control.

If the observed incident-round reduction in stage IV diagnoses represents true downstaging to stage III, it could produce meaningful population health gains. However, this conditional estimate is not evidence of mortality reduction; longer follow-up is needed to distinguish benefit from chance, lead-time and length biases, overdiagnosis, and differences in tumor biology.